ERLOTINIB IN NON-SMALL CELL LUNG CANCER: EXPERIENCE OF CLINICAL HOSPITAL FOR LUNG DISEASES »JORDANOVAC«
Autori:
Sanja Pleština, Miroslav Samaržija, Stjepko Pleština, Nabil Chalfe, Ervin Žuljević
Sažetak
Sažetak. Inhibitori tirozin-kinaze receptora za epidermalni čimbenik rasta posljednjih su godina doveli do produljenja preživljenja i poboljšanja kvalitete života bolesnika s uznapredovalim karcinomom pluća nemalih stanica, nakon neuspjeha liječenja najmanje jednom linijom kemoterapije. U Klinici za plućne bolesti »Jordanovac« erlotinibom smo liječili 36 bolesnika u III.B i IV. stadiju bolesti. U 4 bolesnika (11%) za liječenja erlotinibom došlo je do potpune regresije mjerljivog tumora, u petero (14%) potvrđena je djelomična regresija tumora, dok je stabilnu bolest imalo 14 bolesnika (39%). Evidentnu kliničku korist primijenjenog liječenja erlotinibom imala su, dakle, ukupno 23 bolesnika, odnosno njih 64%. Podnošljivost liječenja bila je pritom vrlo dobra. Ovi su rezultati prvo hrvatsko iskustvo, a u skladu su s podacima objavljenim u literaturi, unekoliko ih čak i nadmašuju. Primjena erlotiniba velik je napredak u liječenju bolesnika s uznapredovalim karcinomom pluća nemalih stanica u Hrvatskoj.
Summary
Summary. Treatment with erlotinib, an inhibitor of the epidermal growth factor receptors, has significantly improved the overall survival rate and quality of life in patients with non-small cell lung cancer who had failed the standard first- or second-line chemotherapy. In Clinical hospital for lung diseases »Jordanovac« a total of 36 patients were treated with erlotinib. The response rate was as follows: in four patients (11%) complete response was achieved, in five (4%) partial response, while fourteen patients (39%) had stable disease. Hence, the evident clinical benefit of treatment with erlotinib was registered in 23 patients (64%) altogether. The treatment was well tolerated and it was not associated with significant toxicity. Our results confirm the antitumour efficacy of erlotinib and show a clear treatment benefit for patients with non-small cell lung cancer in our country.
